Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Advanced Science

卷:8

written on behalf of the AME Lung Cancer Collaborative Group¹  Hao Wang²  Yu Liu²  Yayi He²  Peixin Chen²  Caicun Zhou²  Hui Sun²  Fabrizio Tabbò³  Junji Uchino⁴  Yang Yang⁵  Henry S. Park⁶  Xinyi Liu⁷  Mingyan Xu⁷  Guifeng Liu⁷  Xiaoni Zhang⁷  Lele Song⁷  Shiying Dang⁷  Shifu Chen⁷  Xiaobin Li⁷  Paul Hofman⁸  Kan He⁹  Jiawei Dai⁹  Jose M. Pacheco¹⁰ 

[1] ;

[2] Department of Medical Oncology Shanghai Pulmonary Hospital and Thoracic Cancer Institute Tongji University School of Medicine No. 507, Zhengmin Road, Yangpu District Shanghai 200433 P. R. China;

[3] Department of Oncology University of Turin San Luigi Hospital Orbassano Turin 10043 Italy;

[4] Department of Pulmonary Medicine Kyoto Prefectural University of Medicine Kyoto 602‐8566 Japan;

[5] Department of Surgery, Shanghai Pulmonary Hospital Tongji University School of Medicine No. 507, Zhengmin Road, Yangpu District Shanghai 200433 P. R. China;

[6] Department of Therapeutic Radiology Yale University School of Medicine New Haven CT 06511 USA;

[7] HaploX Biotechnology, Co., Ltd. 8th floor, Auto Electric Power Building, Songpingshan Road, Nanshan District Shenzhen Guangdong 518057 P. R. China;

[8] Laboratory of Clinical and Experimental Pathology FHU OncoAge BB‐0033‐00025 Pasteur Hospital University Côte d'Azur 30 avenue de la voie romaine, Nice cedex 01 Nice 06001 France;

[9] SJTU‐Yale Joint Center for Biostatistics and Data Science Department of Bioinformatics and Biostatistics School of Life Sciences and Biotechnology Shanghai Jiao Tong University Shanghai 200240 China;

[10] Thoracic Oncology Program Division of Medical Oncology Department of Internal Medicine University of Colorado Cancer Center Aurora CO 80045 USA;

关键词: chemotherapy;    lung cancer;    NSCLC;    SCLC;    subtype;    TMB;   

DOI  :  10.1002/advs.202003263

来源: DOAJ

【 摘 要 】

Abstract Evaluating the therapeutic response and survival of lung cancer patients receiving first‐line chemotherapy has always been difficult. Limited biomarkers for evaluation exist and as a result histology represents an empiric tool to guide therapeutic decision making. In this study, molecular signatures associated with response and long‐term survival of lung cancer patients receiving first‐line chemotherapy are discovered. Whole‐exome sequencing is performed on pretherapeutic tissue samples of 186 patients [145 non‐small cell lung cancer (NSCLC) and 41 small cell lung cancer (SCLC)]. On the basis of genomic alteration characteristics, NSCLC patients can be classified into four subtypes (C1–C4). The long‐term survival is similar among different subtypes. SCLC patients are also divided into four subtypes and significant difference in their progression free survival is revealed (P < 0.001). NSCLC patients can be divided into three subtypes (S1–S3) based on TMB. A trend of worse survival associated with higher TMB in subtype S3 than in S1+S2 is found. In contrast, no significant correlations between molecular subtype and therapeutic response are observed. In conclusion, this study identifies several molecular signatures associated with response and survival to first‐line chemotherapy in lung cancer.

【 授权许可】

Unknown